ABSTRACT
Background. There is a continued need for therapeutics for the treatment of COVID-19, including intramuscular (IM) agents, which will enable broader use across a variety of healthcare delivery settings. Methods. COMET-PEAK (NCT04779879) is a 3-part study evaluating the safety, tolerability, pharmacokinetics (Part A), and viral pharmacodynamics (PD) of sotrovimab as treatment in adults >= 18 years with early mild/moderate COVID-19. In Parts B and C, the safety, tolerability and viral PD of sotrovimab administered as a 500 mg intravenous (IV) infusion or as a 500 mg or 250 mg IM injection, respectively, was evaluated. The primary objective for Parts B and C was to compare the virologic response of sotrovimab IM to IV, with an endpoint of mean area under the curve (AUC) of SARS-CoV-2 viral load as measured by qRT-PCR from Day 1 to Day 8 (AUCD1-8) in nasopharyngeal swabs and predefined 90% confidence interval (CI) limits of 0.5-2.0 indicating equivalence. Results. A total of 167 and 157 participants were enrolled in Part B and C, respectively, from February-July 2021. The median age of participants was 47 and 42 years in Part B and C, respectively, and ~50% had >= 1 risk factor for progression to severe disease. The viral load at baseline and through Day 29 of follow-up for each arm is shown in Table 1 and Figure 1. The primary objective was met for both study parts: the ratio of the least square geometric mean viral load AUC(D1-8) of sotrovimab IM vs IV was 1.04 (90% CI, 0.98, 1.09) and 1.02 (90% CI, 0.94, 1.11), for Part B and C, respectively. Through Day 29 of follow-up, the most common adverse event was injection site reactions (ISRs) in the IM arms. A total of 10 (12%) participants in the 500 mg IM group and 4 (5%) participants in the 250 mg IM group experienced an ISR, all Grade 1. Serious adverse events were uncommon, and related to COVID-19 progression, including one death in the 250 mg IM arm (Table 2). ISRs aside, there were few treatment-related AEs (2/84 IV, 1/82 IM) in Part B, none serious. Conclusion. IM administration of sotrovimab 500 mg and 250 mg each demonstrated equivalence to 500 mg sotrovimab IV in viral load assessments. Overall, there were no treatment-related serious AEs and sotrovimab was well tolerated. An 500 mg IM formulation will allow for expanded treatment potential with sotrovimab.
ABSTRACT
The COVID-19 is a crisis of unprecedented magnitude, which has resulted in countless casualties and security troubles. In view of recent events of corona virus people are required to wear face masks to protect themselves from getting infected. As a result, a good portion of face (nose and mouth) is hidden by the mask and hence the facial recognition becomes difficult. Many organizations use facial recognition as a means of authentication. Researchers focus on developing rapid and efficient solutions to deal with the ongoing coronavirus pandemic by coming up with suggestions for handling the facial recognition problem. This research paper aims to identify the person, while the face is covered with a facial mask with only eyes and forehead being exposed. The first step involves marking the facial region. Next, using the data set, we will implement an object detection model YOLOv3 to identify unmasked and masked faces. The YOLO v3 object detection model is the best performing model with a detection time of 0.012 s, F1 score of 0.90 and mAP score of 0.92. Experimental results on Real-World Masked-Face-Data set show high recognition performance.
ABSTRACT
The COVID-19 is a crisis of unprecedented magnitude, which has resulted in countless casualties and security troubles. In view of recent events of corona virus people are required to wear face masks to protect themselves from getting infected. As a result, a good portion of face (nose and mouth) is hidden by the mask and hence the facial recognition becomes difficult. Many organizations use facial recognition as a means of authentication. Researchers focus on developing rapid and efficient solutions to deal with the ongoing coronavirus pandemic by coming up with suggestions for handling the facial recognition problem. This research paper aims to identify the person, while the face is covered with a facial mask with only eyes and forehead being exposed. The first step involves marking the facial region. Next, using the data set, we will implement an object detection model YOLOv3 to identify unmasked and masked faces. The YOLO v3 object detection model is the best performing model with a detection time of 0.012 s, F1 score of 0.90 and mAP score of 0.92. Experimental results on Real-World Masked-Face-Data set show high recognition performance.
ABSTRACT
Background. Migrant farmworkers have been identified as a vulnerable population for Severe Acute Respiratory Syndrome Novel Coronavirus-2 infection (SARS-CoV-2). The objectives of this study were to detect the SARS-CoV-2 infection (COV19) status among 262 migrant farmworkers in North Florida. Methods. This is a retrospective analysis of the information gathered from migrant workers referred by the Florida Dept. of Health for evaluation. Due to the urgency of returning to Mexico, subjects with which COV19 was detected were reevaluated for detailed medical history. Therefore, subjects that tested negative were later released following CDC guidelines. COV19 status was determined using an RNA qualitative nucleic acid amplification test (NAAT) from nasopharyngeal swabs collected over a three-day period. Variables collected include demography, symptoms, temperature, comorbidities, medication use, and vaccine status. Statistical significance for categorical variables was assessed using χ 2 test or Fisher's exact test where appropriate. Remaining variables were assessed using basic descriptive analysis. Results. From the 262 subjects tested, 6 missed the follow up visit and data was unavailable. All were Mexican males, age 18-67 years, with positivity rate of 35.1%. Among the 92 (+) subjects, the average age was 34.1 years and 34.5 among the 164 (-) subjects, (p=< 0.77). The symptoms and temperatures are in Table 1. Three of the 92 COV19 (+) subjects were hospitalized, non-ICU and made an uneventful recovery. 59.8% of COV19 (+) subjects were asymptomatic. Among the 92 (+) subjects, 20.7% reported using acetaminophen within the last 60 days. The most common reported comorbidity was being a former smoker or current smoker, at 12.0% and 4.3% respectively. Conclusion. The COVID-19 pandemic has highlighted migrant workers as a vulnerable population with astronomical COV19 rates, compared to others in FL (14/100,000). They are impoverished, uneducated, undocumented, uninsured and employed to perform arduous physical labor and it is essential to provide basic healthcare to prevent the spread of COV19.